Navigation Links
Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine

DEERFIELD, Ill., March 29, 2007 /PRNewswire-FirstCall/ -- Baxter International Inc. today announced final Phase I/II data for its adjuvant-free investigational pandemic H5N1 influenza vaccine and plans to initiate a Phase III clinical trial of the candidate vaccine in Europe to confirm the study results.

The Phase I/II study indicated that Baxter's H5N1 candidate vaccine is highly immunogenic at low doses, and induces substantial levels of cross immunity against widely divergent H5N1 strains. The open-label, multi-center Phase III trial is designed to evaluate the safety and efficacy of Baxter's adjuvant-free, whole-virus candidate vaccine. Vaccinations will begin in the first half of this year and results of the Phase III trial are scheduled to be available by the end of 2007.

"The results of the Phase I/II clinical trial suggested that this candidate vaccine may provide protection against divergent strains of virus, even at low dose levels without an adjuvant," said John Oxford, professor of Virology, The Queen Mary School of Medicine, London, United Kingdom. "The Phase III clinical trial is designed to confirm these findings and provide a solid measure of the vaccine's potential to protect a large number of people before and during a possible pandemic."

Baxter's candidate H5N1 vaccine is derived from H5N1 strain A/Vietnam/1203/2004. Its antigen composition and structure closely resembles the actual pathogen circulating in nature. The candidate vaccine induces an immune response (both cell and antibody mediated) that is similar to the body's defense against a natural virus, without the need to incorporate additional agents (adjuvants) to enhance immune response. It is manufactured using the company's proprietary vero cell technology, which produces high- yield vaccine more quickly than traditional approaches because it is not produced in eggs. Baxter's candidate vaccine is the first cell-
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Baxter Presents Phase I Inhaled Insulin Study Results at Respiratory Drug Delivery Conference
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:9/2/2014)... commands the vital signs monitoring devices market with ... . The North American and European vital signs ... $907.0 million, respectively, by the end of 2013. They ... rising number of elderly people across these economies. The ... demand owing to the rising demand for home health ...
(Date:9/2/2014)... Reportlinker.com announces that a new market ... Acute Heart Failure Global Clinical Trials Review, ... Acute Heart Failure Global Clinical Trials ... clinical trial report, "Acute Heart Failure Global Clinical ... Acute Heart Failure clinical trial scenario. This report ...
(Date:9/2/2014)... 2014   Santa Clara dentist , Dr. ... for Invisalign. Invisalign is an orthodontic system that uses ... often the orthodontic treatment of choice for older teens ... it. For a limited time, patients can try Invisalign ... the usual cost. This offer cannot be combined, and ...
Breaking Medicine Technology:Market of Vital Signs Monitoring Devices Forecast to 2018 2Market of Vital Signs Monitoring Devices Forecast to 2018 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8Santa Clara Cosmetic Dentist, Dr. Alan Frame, is Now Offering a Special on Invisalign 2
... 2007 - CELSION CORPORATION,(AMEX:CLN) today announced the ... using ThermoDox(R), to treat non-resectable liver,cancer. The ... Research,and Development Agreement (CRADA) was performed at ... Institutes of Health, under,the leadership of Dr. ...
... NEW YORK--(BUSINESS WIRE)--May 30, 2007 - INNOVIVE ... data from a Phase I,trial of INNO-406, ... for Gleevec(R)-resistant or,treatment-intolerant chronic myelogenous leukemia, will ... Clinical Oncology Annual,Meeting. The meeting takes place ...
Cached Medicine Technology:Celsion Completes Enrollment in Phase I Liver Cancer Study 2Celsion Completes Enrollment in Phase I Liver Cancer Study 3Innovive Pharmaceuticals to Present Interim Data from Phase I Study,of INNO-406 at the American Society of Clinical Oncology Annual,Meeting 2
(Date:9/2/2014)... York, NY (PRWEB) September 02, 2014 ... soccer tickets. The first week in September will be ... Teams from Brazil, Colombia, Mexico, Chile, Ecuador and Bolivia ... The following matches will take place between September 5th - ... Stadium on Tuesday, September 9th , Mexico vs. ...
(Date:9/2/2014)... NY (PRWEB) September 02, 2014 The ... VisitandCare.com , was designed to help doctors manage foreign ... to boost patient conversion rates and clink revenue. Since ... 60 percent increase in sales revenue and a 70 ... CRM software in their own healthcare practices. , With ...
(Date:9/2/2014)... you are hospitalized, but your outpatient doctor does ... office for follow-up care, but your doctor does ... stay? Missing or incomplete communication from hospitals ... to poor experiences and lead to hospital readmissions. ... implementing guidelines can improve hospitals, communication during patient ...
(Date:9/2/2014)... Experimental Biology and Medicine that appears ... and medicine of microphysiological systems" and describes the ... Program directed by the National Center for Advancing ... Health (NIH) and funded in part by the ... Agency (DARPA) and the Food and Drug Administration ...
(Date:9/2/2014)... Ohio (PRWEB) September 02, 2014 For ... managed IT security and network services company, has been ... nation. Inc. magazine's Inc. 5000 list highlights America's fastest ... each year since the list inception in 2007. , ... has grown 144 percent over the past three years. ...
Breaking Medicine News(10 mins):Health News:Ticket Down Substantially Slashes Ticket Prices on Brazil vs. Ecuador Tickets, Brazil vs. Colombia Tickets, Mexico vs. Chile Tickets and Mexico vs. Bolivia Tickets 2Health News:Ticket Down Substantially Slashes Ticket Prices on Brazil vs. Ecuador Tickets, Brazil vs. Colombia Tickets, Mexico vs. Chile Tickets and Mexico vs. Bolivia Tickets 3Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 2Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 3Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 4Health News:Can data motivate hospital leaders to improve care transitions? 2Health News:Microphysiological systems will revolutionize experimental biology and medicine 2Health News:Microphysiological systems will revolutionize experimental biology and medicine 3Health News:CentraComm Named to Inc. 5000 for 8th Consecutive Year 2
... battle super bugs, including MRSA, has found its way to ... as Tygacil, is one of the few new antibiotics to ... ,Micro organisms have undergone mutations that enabled them ... infections, such as MRSA, in hospitals. ,The new ...
... new study suggests that male circumcision could significantly reduce ... findings that has been published in the Journal PLoS ... that suggested circumcision reduced HIV infection risk in heterosexual ... researchers have used that data and conducted the research, ...
... study in the July issue of Archives of General Psychiatry, ... fact more prone to depression. //The study on more than ... percent increased risk of developing mood and anxiety disorders including, ... is an important public health issue because both of these ...
... agreed to reconduct lab tests to find out whether a ... as early as 2003, after eight of its scientists alleged ... Ministry of Health said it was conducting new lab tests ... ,"In accordance with World Health Organisation and China's diagnostic standards ...
... compares two common inhalers for patients suffering from ... reduces respiratory-related hospitalizations and respiratory deaths, but the ... of cases -- increases respiratory deaths. ... 22 trials with 15,276 participants found that common ...
... Researchers at the Institute Of Cancer Research have discovered a ... the disease.// ,It is found that if a ... being diagnosed with breast cancer doubles. This would serve as ... risk of cancer and thereby help treat and prevent the ...
Cached Medicine News:Health News:New Drugs To Combat Mutant Bugs 2Health News:Practise Of Male Circumcision In Africa May Reduce HIV Risks 2Health News:COPD Patients Using Beta-agonist Inhalers Are at Risk 2
Exidine® 2% CHG Brushless Surgical Scrub offers exceptional persistence and broad-spectrum antimicrobial activity....
... FDA approved, Avagard antiseptic hand prep ... hand scrub brushes and antimicrobial soaps. ... hands for surgery, it's fast-acting and ... for up to six hours without ...
... antimicrobial skin cleanser will not leave your ... frequent washings. With persistent Antimicrobial action, CHG ... microorganisms, including gram-negative and gram-positive bacteria, fungi, ... a 15 second hand wash. The solution ...
Upon application to intact skin, Skin-Prep* protective wipes forms a protective film that prepares the skin for the attachment of drainage tubes, external catheters, adhesive dressings and can be...
Medicine Products: